In a clinical trial of refractory or metastatic cervical cancer patients treated with nivolumab, the overall response rates (ORR) were 2/10 (20%) in PD-L1 positive patients and 1/6 (16.7%) in PD-L1 negative patients. The gene discussed is CD274; the disease is cervical cancer.